Warning! GuruFocus detected
4 Severe warning signs
with S2L.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Bausch & Lomb Corp
NAICS : 333314
SIC : 3912
ISIN : CA0717051076
Description
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.06 | |||||
| Equity-to-Asset | 0.48 | |||||
| Debt-to-Equity | 0.74 | |||||
| Debt-to-EBITDA | 8.21 | |||||
| Interest Coverage | 0.48 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 0.89 | |||||
| Beneish M-Score | -2.43 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.1 | |||||
| 3-Year EBITDA Growth Rate | -3.2 | |||||
| 3-Year EPS without NRI Growth Rate | 7.7 | |||||
| 3-Year Book Growth Rate | -8.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 28.23 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 5.85 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 23.56 | |||||
| 9-Day RSI | 25.06 | |||||
| 14-Day RSI | 27.83 | |||||
| 3-1 Month Momentum % | -10.29 | |||||
| 6-1 Month Momentum % | 12.95 | |||||
| 12-1 Month Momentum % | 7.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | |||||
| Quick Ratio | 1.01 | |||||
| Cash Ratio | 0.18 | |||||
| Days Inventory | 206.37 | |||||
| Days Sales Outstanding | 71.49 | |||||
| Days Payable | 85.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.2 | |||||
| Shareholder Yield % | -20.99 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 60.92 | |||||
| Operating Margin % | 4.02 | |||||
| Net Margin % | -6.55 | |||||
| FCF Margin % | -1.33 | |||||
| ROE % | -4.77 | |||||
| ROA % | -2.36 | |||||
| ROIC % | 2.11 | |||||
| 3-Year ROIIC % | 2.01 | |||||
| ROC (Joel Greenblatt) % | 7.48 | |||||
| ROCE % | 1.44 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 21.35 | |||||
| PS Ratio | 1.18 | |||||
| PB Ratio | 0.84 | |||||
| Price-to-Operating-Cash-Flow | 24.64 | |||||
| EV-to-EBIT | 62.27 | |||||
| EV-to-Forward-EBIT | 30.49 | |||||
| EV-to-EBITDA | 17.27 | |||||
| EV-to-Forward-EBITDA | 14.13 | |||||
| EV-to-Revenue | 2.17 | |||||
| EV-to-Forward-Revenue | 1.37 | |||||
| EV-to-FCF | -167.17 | |||||
| Price-to-GF-Value | 0.78 | |||||
| Earnings Yield (Greenblatt) % | 1.61 | |||||
| FCF Yield % | -1.1 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bausch & Lomb Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 4,440.74 | ||
| EPS (TTM) (€) | -0.842 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 34.73 | ||
| 14-Day RSI | 27.83 | ||
| 14-Day ATR (€) | 0.307677 | ||
| 20-Day SMA (€) | 14.93 | ||
| 12-1 Month Momentum % | 7.53 | ||
| 52-Week Range (€) | 12.6 - 19.4 | ||
| Shares Outstanding (Mil) | 352.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bausch & Lomb Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bausch & Lomb Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Bausch & Lomb Corp Frequently Asked Questions
What is Bausch & Lomb Corp(STU:S2L)'s stock price today?
The current price of STU:S2L is €13.90. The 52 week high of STU:S2L is €19.40 and 52 week low is €12.60.
When is next earnings date of Bausch & Lomb Corp(STU:S2L)?
The next earnings date of Bausch & Lomb Corp(STU:S2L) is 2025-05-01 Est..
Does Bausch & Lomb Corp(STU:S2L) pay dividends? If so, how much?
Bausch & Lomb Corp(STU:S2L) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers